Antipeptide Antibody Responses following Intranasal Immunization: Effectiveness of Mucosal Adjuvants
Toxicity is a major factor limiting the development and use of potent adjuvants for human mucosally delivered vaccines. Novel adjuvant formulations have recently become available, and in the present study two have been used for intranasal immunization with a synthetic peptide immunogen (MAP-M2). Thi...
Αποθηκεύτηκε σε:
| Εκδόθηκε σε: | Infect Immun |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society for Microbiology (ASM)
2000
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101701/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10948106/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.68.9.4923-4929.2000 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|